These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 31327399)

  • 1. Interfering with leukocyte trafficking in Crohn's disease.
    Biswas S; Bryant RV; Travis S
    Best Pract Res Clin Gastroenterol; 2019; 38-39():101617. PubMed ID: 31327399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.
    Thomas S; Baumgart DC
    Inflammopharmacology; 2012 Feb; 20(1):1-18. PubMed ID: 22205271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease.
    Panés J; Salas A
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S633-S640. PubMed ID: 30137311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts.
    Pérez-Jeldres T; Tyler CJ; Boyer JD; Karuppuchamy T; Bamias G; Dulai PS; Boland BS; Sandborn WJ; Patel DR; Rivera-Nieves J
    Inflamm Bowel Dis; 2019 Jan; 25(2):270-282. PubMed ID: 30165490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrin antagonists as potential therapeutic options for the treatment of Crohn's disease.
    McLean LP; Cross RK
    Expert Opin Investig Drugs; 2016; 25(3):263-73. PubMed ID: 26822204
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-Integrins for the Treatment of Inflammatory Bowel Disease: Current Evidence and Perspectives.
    Gubatan J; Keyashian K; Rubin SJS; Wang J; Buckman CA; Sinha S
    Clin Exp Gastroenterol; 2021; 14():333-342. PubMed ID: 34466013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natalizumab for induction of remission in Crohn's disease.
    MacDonald JK; McDonald JW
    Cochrane Database Syst Rev; 2007 Jan; (1):CD006097. PubMed ID: 17253580
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Natalizumab for induction of remission in Crohn's disease.
    Macdonald JK; McDonald JW
    Cochrane Database Syst Rev; 2006 Jul; (3):CD006097. PubMed ID: 16856112
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Strategies that target leukocyte traffic in inflammatory bowel diseases: recent developments.
    Rivera-Nieves J
    Curr Opin Gastroenterol; 2015 Nov; 31(6):441-8. PubMed ID: 26398681
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-Integrins in Ulcerative Colitis and Crohn's Disease: What Is Their Place?
    Khanna R; Mosli MH; Feagan BG
    Dig Dis; 2016; 34(1-2):153-9. PubMed ID: 26982012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gut-Selective Integrin-Targeted Therapies for Inflammatory Bowel Disease.
    Lamb CA; O'Byrne S; Keir ME; Butcher EC
    J Crohns Colitis; 2018 Aug; 12(suppl_2):S653-S668. PubMed ID: 29767705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Vedolizumab in the treatment of Crohn's disease].
    Gisbert JP; Domènech E
    Gastroenterol Hepatol; 2015 May; 38(5):338-48. PubMed ID: 25619903
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab in the treatment of Crohn's disease patients.
    Pagnini C; Arseneau KO; Cominelli F
    Expert Opin Biol Ther; 2017 Nov; 17(11):1433-1438. PubMed ID: 28832222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects.
    Mosli MH; Rivera-Nieves J; Feagan BG
    Drugs; 2014 Mar; 74(3):297-311. PubMed ID: 24452878
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting leukocyte trafficking for the treatment of inflammatory bowel disease.
    Arseneau KO; Cominelli F
    Clin Pharmacol Ther; 2015 Jan; 97(1):22-8. PubMed ID: 25670380
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: anti-adhesion therapies for inflammatory bowel disease.
    Lobatón T; Vermeire S; Van Assche G; Rutgeerts P
    Aliment Pharmacol Ther; 2014 Mar; 39(6):579-94. PubMed ID: 24479980
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.